查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1716301

2032 年退伍軍人菌檢測市場預測：按類型、樣本類型、應用、最終用戶和地區進行的全球分析

Legionella Testing Market Forecasts to 2032 - Global Analysis By Type (Culture Methods, Urine Antigen Testing, Polymerase Chain Reaction, Serology and Direct Fluorescent Antibody Test), Sample Type, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，全球退伍軍人菌檢測市場預計在 2025 年將達到 4.0163 億美元，到 2032 年將達到 8.7136 億美元，預測期內的複合年成長率為 11.7%。

退伍軍人菌檢測是檢測水系統中退伍軍人菌的存在的關鍵過程，有助於預防退伍退伍軍人菌症（一種潛在的嚴重肺炎）。該測試通常在冷卻塔、飯店、辦公室和醫院進行，以確保熱水浴缸、管道系統和裝飾噴泉等水源的安全。通常使用免疫學測定、聚合酵素鏈鎖反應(PCR) 和培養技術來收集和分析水樣本。此外，水安全管理計畫應包括定期退伍軍人菌檢測，以支持公共衛生和法規遵循。

根據美國疾病管制與預防中心 (CDC) 的數據，2015 年至 2020 年間，美國報告的因水傳播疾病爆發而住院的人數中，97% 是退伍軍人菌引起的，死亡人數中，98% 是由美國菌引起的。

退伍軍人菌病發生率上升

退伍退伍軍人菌病的爆發不僅危險，而且還會給設施營運者帶來嚴重的法律和經濟後果。例如，2024年8月，澳洲維多利亞州記錄了71例退伍軍人菌病確診病例和1例死亡病例，引起公眾關注和監管審查的增加。退伍軍人菌檢測市場的主要驅動力是全球退伍軍人菌病病例的增加，根據美國疾病管制與預防中心報告，2000 年至 2018 年間，美國報告的軍團病病例數增加了五倍多。此外，日益加重的疾病負擔迫使醫療機構、市政當局和建築物業主實施積極的檢測通訊協定，以檢測並消滅供水系統中的退伍軍人菌。

昂貴的先進測試技術

快速免疫檢測、聚合酵素鏈鎖反應(PCR) 和次世代定序(NGS) 等先進檢測技術儘管速度快、準確，但價格昂貴。較小設施和發展中地區的發展通常受到專用設備、訓練有素的人員和專有試劑成本的限制。預算限制迫使許多設施，特別是那些資源有限的設施，使用傳統的培養方法，儘管這需要時間才能完成。此外，這種經濟障礙可能會阻礙市場發展，特別是在衛生基礎設施尚未發達且退伍軍人菌尚未成為主要問題的地區。

結合智慧水資源管理系統

隨著智慧建築技術的日益普及，將退伍軍人菌檢測納入更大的水質監測系統成為可能，智慧建築技術可以自動控制水溫、識別停滯情況並通知操作員有利於退伍軍人菌生長的條件。結合自動或遠端退伍軍人菌檢測，這些系統可以加快檢測和合規速度，尤其是在較大的商業和工業設施中。此外，能夠提供包括退伍軍人菌檢測在內的全面數位水資源管理解決方案的公司將在智慧建築和設施管理市場領域佔據有利地位，從而吸引資本。

缺乏基礎設施和技術純熟勞工

許多實驗室和現場檢測團隊需要高技能的微生物學家和技術人員來執行先進的退伍軍人菌診斷，例如 PCR 和培養確認。缺乏合格專業人員限制了服務的擴充性，尤其是在農村和開發中地區。此外，某些國家缺乏實驗室處理、運輸和水體採樣的標準化基礎設施，可能會導致結果不佳。技術能力的缺乏限制了發展並削弱了人們對退伍軍人菌計畫發展的信心。

COVID-19的影響：

COVID-19 疫情以多種方式影響了退伍軍人菌檢測市場。一方面，由於用水量減少而導致大面積建築物關閉和封鎖，管道系統中的積水增加了退伍軍人菌生長的可能性。這導致人們的意識增強和檢測需求激增，尤其是在準備安全重新開放的醫院、住宿設施和商業建築中。然而，尤其是在疫情初期，檢測活動因供應鏈中斷、場地訪問受限和營運預算減少而暫時受到阻礙。但最終，這場危機凸顯了定期環境監測的價值，退伍軍人菌檢測已成為後疫情時代設施管理和公共衛生的重要組成部分。

預計尿液抗原檢測（UAT）領域將成為預測期內最大的領域。

預計預測期內尿液抗原檢測（UAT）領域將佔據最大的市場佔有率。主要原因是該方法快速、易於使用且靈敏度高，特別是對於識別導致大多數退伍軍人菌病病例的嗜肺性退伍軍人桿菌1 血清群而言。 UAT 可以使用非侵入性尿液樣本在數小時內提供結果，使其成為臨床和醫院環境中快速診斷和開始治療的首選方法。此外，UAT 之所以能夠在市場上領先於培養、PCR 和血清學等其他檢測方法，關鍵因素在於其易於使用、被廣泛接受以及能夠在疫情調查期間促進廣泛的篩檢。

預計生物膜部分在預測期內將出現最高的複合年成長率。

預計生物膜部分將在預測期內見證最高的成長率。生物膜是退伍軍人菌的長期家園，保護退伍軍人菌免受惡劣環境和消毒劑的侵害。隨著對生物膜在反覆污染中所扮演的角色的認知不斷增加，對生物膜特定測試的需求也在增加。現在可以透過先進的採樣和分子診斷技術更準確地檢測出嵌入在系統組件和管道表面的細菌。此外，由於對生物膜測試的投資以及在冷卻塔、醫院和工業環境中擴大使用主動水安全管理計劃，該領域的成長速度顯著加快。

佔比最大的地區：

由於先進診斷技術的廣泛採用、廣泛的認知度以及嚴格的法律規範，預計北美地區將在預測期內佔據最大的市場佔有率。尤其是在美國，疾病預防控制中心和職業安全與健康管理局等組織對水安全有嚴格的監督和規定，要求對商業建築、老年護理院和醫療機構進行定期檢測。完善的醫療保健基礎設施、一流的診斷公司以及退伍軍人菌的定期爆發凸顯了積極檢測的必要性。此外，由於強力的公共衛生宣傳活動和對感染控制的投資，北美目前是退伍軍人菌檢測的主要區域市場。

複合年成長率最高的地區：

在預測期內，由於工業基礎設施的成長、快速的都市化以及對水傳播感染疾病的認知的提高，預計亞太地區將呈現最高的複合年成長率。在中國、印度和東南亞等國家，醫院、飯店和製造工廠的水安全變得越來越重要。政府努力提高公共衛生標準和國際診斷公司的擴張正在導致先進的退伍軍人菌檢測解決方案更廣泛的應用。此外，由於環境衛生法規的加強和基礎設施的老化，亞太市場預計將快速擴張，成為市場參與企業關注的重點地區。

免費客製化服務

訂閱此報告的客戶可享有以下免費自訂選項之一：

  • 公司簡介
    • 全面分析其他市場參與者（最多 3 家公司）
    • 主要企業的SWOT分析（最多3家公司）
  • 地理細分
    • 根據客戶興趣對主要國家市場進行估計、預測和複合年成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 研究範圍
  • 調查方法
    • 資料探勘
    • 數據分析
    • 數據檢驗
    • 研究途徑
  • 研究材料
    • 主要研究資料
    • 次級研究資訊來源
    • 先決條件

第3章市場走勢分析

  • 驅動程式
  • 限制因素
  • 機會
  • 威脅
  • 應用分析
  • 最終用戶分析
  • 新興市場
  • COVID-19的影響

第4章 波特五力分析

  • 供應商的議價能力
  • 買家的議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭對手之間的競爭

第5章全球退伍軍人菌檢測市場（按類型）

  • 培養方法
  • 尿液抗原檢測（UAT）
  • 聚合酵素鏈鎖反應（PCR）
  • 血清學
  • 直接螢光抗體（DFA）檢測

6. 全球退伍軍人菌檢測市場（依樣本類型）

  • 水
  • 生物膜
  • 棉花棒樣本

7. 全球退伍軍人菌檢測市場（按應用）

  • 水質檢測
    • 微生物培養
    • DFA染色
    • PCR
  • 體外診斷（IVD）測試
    • 血液培養和痰液檢查
    • 尿液抗原檢測
    • DFA染色
    • PCR
  • 其他用途

8. 全球退伍軍人菌檢測市場（依最終用戶）

  • 醫院和診所
  • 診斷實驗室
  • 水處理業
  • 其他最終用戶

9. 全球退伍軍人菌檢測市場（按地區）

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲地區

第10章 重大進展

  • 協議、夥伴關係、合作和合資企業
  • 收購與合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第11章 公司概況

  • Danaher Corporation
  • Quidel Corporation
  • Thermo Fisher Scientific, Inc.
  • Eurofins Scientific
  • IDEXX Corporation
  • Abbott Laboratories
  • Merck KGaA
  • Eiken Chemical Co., Ltd.
  • Aquacert Ltd.
  • Takara Bio, Inc.
  • LuminUltra Technologies Ltd.
  • Becton, Dickinson & Company
  • Pro-Lab Diagnostics, Inc.
  • Qiagen NV
  • Bio-Rad Laboratories, Inc.
Product Code: SMRC29112

According to Stratistics MRC, the Global Legionella Testing Market is accounted for $401.63 million in 2025 and is expected to reach $871.36 million by 2032 growing at a CAGR of 11.7% during the forecast period. Legionella testing is a critical process used to detect the presence of Legionella bacteria in water systems, helping to prevent Legionnaires' disease-a potentially severe form of pneumonia. Frequently carried out in cooling towers, hotels, offices, and hospitals, this testing guarantees the safety of water sources like hot tubs, plumbing systems, and ornamental fountains. Water sample collection and analysis usually entails the use of immunological assays, polymerase chain reaction (PCR), or culture techniques. Moreover, water safety management plans must include routine Legionella testing to support public health and regulatory compliance.

According to the Centers for Disease Control and Prevention (CDC), Legionella bacteria were responsible for 97% of hospitalizations and 98% of deaths resulting from reported waterborne disease outbreaks in the United States between 2015 and 2020.

Market Dynamics:

Driver:

Rising rate of legionnaires illness

Legionnaires' disease outbreaks are not only dangerous but can also have serious legal and financial ramifications for facility operators. For instance, in August 2024, Victoria, Australia, recorded 71 confirmed cases and one death from Legionnaires' disease, raising public concern and regulatory scrutiny. The primary driver of the Legionella testing market is the increasing number of Legionnaires disease cases worldwide, with the CDC reporting that reported cases of the disease more than fivefold increased in the United States between 2000 and 2018. Additionally, this increasing burden of disease is forcing healthcare facilities, municipalities, and building owners to implement proactive testing protocols to detect and eradicate Legionella bacteria from water systems.

Restraint:

Expensive advanced testing technologies

Advanced detection techniques such as rapid immunoassays, polymerase chain reaction (PCR), and next-generation sequencing (NGS) are expensive despite their speed and accuracy. Adoption in smaller facilities and developing regions is frequently constrained by the expense of specialized equipment, trained personnel, and proprietary reagents. Budgetary constraints force many facilities, particularly those with limited resources, to use traditional culture methods even though they take longer to complete. Furthermore, this financial obstacle has the potential to impede market expansion, especially in areas where health infrastructure is still being developed or where Legionella is not yet a major concern.

Opportunity:

Combining intelligent water management systems

Incorporating Legionella testing into larger water quality monitoring systems is made possible by the increasing use of smart building technology, which can automatically control water temperature, identify stagnation, and notify operators of conditions that are conducive to Legionella growth. When combined with automated or remote Legionella detection, these systems can expedite testing and compliance, especially in large commercial or industrial facilities. Moreover, businesses that can provide comprehensive digital water management solutions, including Legionella detection, are well-positioned to capitalize on the smart building and facility management market sectors.

Threat:

Absence of infrastructure and skilled workers

Highly skilled microbiologists or technicians are needed by many labs and field testing teams to carry out sophisticated Legionella diagnostics like PCR or culture confirmation. A lack of these qualified experts limits the scalability of services, particularly in rural or developing areas. Furthermore, in certain nations, the absence of standardized infrastructure for laboratory processing, transportation, and water sampling raises the possibility of subpar results. This lack of technical capability restricts development and undermines confidence in growing programs to control Legionella.

Covid-19 Impact:

The COVID-19 pandemic had a mixed impact on the Legionella testing market. On the one hand, water stagnation in plumbing systems during lockdowns due to widespread building closures and decreased water usage raised the possibility of Legionella growth. This led to increased awareness and a spike in testing demand, especially in hospitals, lodging facilities, and business buildings getting ready for a safe reopening. However, particularly in the early phases of the pandemic, testing activities were momentarily hindered by supply chain disruptions, site access restrictions, and decreased operational budgets. But eventually, the crisis highlighted the value of regular environmental monitoring, making Legionella testing an essential part of facility management and public health in the post-pandemic world.

The urine antigen testing (UAT) segment is expected to be the largest during the forecast period

The urine antigen testing (UAT) segment is expected to account for the largest market share during the forecast period. The main reasons for its dominance are its speed, simplicity of use, and high sensitivity, especially when it comes to identifying Legionella pneumophila serogroup 1, which causes the majority of cases of Legionnaires' disease. Because UAT can provide results using non-invasive urine samples in a matter of hours, it is the method of choice for quick diagnosis and treatment initiation in clinical and hospital settings. Moreover, a major factor in its market dominance over other testing techniques like culture, PCR, or serology is its ease of use, broad acceptance, and capacity to facilitate extensive screening during outbreak investigations.

The biofilm segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the biofilm segment is predicted to witness the highest growth rate. Biofilms act as a long-term home for Legionella bacteria, shielding them from harsh environments and disinfectants. There is an increasing need for biofilm-specific testing as knowledge of the part biofilms play in recurring contamination grows. Bacteria embedded in system components and pipe surfaces can now be detected with greater accuracy owing to advanced sampling and molecular diagnostics. Additionally, the segment is growing at a significantly faster rate owing to investments in biofilm testing and the growing use of proactive water safety management programs in cooling towers, hospitals, and industrial settings.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share, driven by the high adoption of advanced diagnostic technologies, broad awareness, and strict regulatory frameworks. Particularly in the United States, strict surveillance and water safety regulations have been put in place by organizations like the CDC and OSHA, which require regular testing in commercial buildings, senior living facilities, and healthcare facilities. The necessity of proactive testing has been emphasized by the existence of a well-established healthcare infrastructure, top diagnostic firms, and regular Legionella outbreaks. Furthermore, North America is now the leading regional market for Legionella testing due to strong public health campaigns and investments in infection control.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR, driven by growing industrial infrastructure, fast urbanization, and growing awareness of waterborne illnesses. Water safety in hospitals, hotels, and manufacturing facilities is becoming increasingly important in countries like China, India, and Southeast Asia. Advanced Legionella testing solutions are becoming more widely used as a result of government initiatives to raise public health standards and the expansion of international diagnostic firms. Moreover, the Asia-Pacific market is expected to expand quickly as environmental health regulations tighten and infrastructure ages, making it a crucial area for industry participants to concentrate on.

Key players in the market

Some of the key players in Legionella Testing Market include Danaher Corporation, Quidel Corporation, Thermo Fisher Scientific, Inc., Eurofins Scientific, IDEXX Corporation, Abbott Laboratories, Merck KGaA, Eiken Chemical Co., Ltd., Aquacert Ltd., Takara Bio, Inc., LuminUltra Technologies Ltd., Becton, Dickinson & Company, Pro-Lab Diagnostics, Inc., Qiagen N.V. and Bio-Rad Laboratories, Inc.

Key Developments:

In February 2025, Thermo Fisher Scientific Inc. announced that the company has entered into a definitive agreement with Solventum to acquire Solventum's Purification & Filtration business for approximately $4.1 billion in cash. Solventum's Purification & Filtration business is a leading provider of purification and filtration technologies used in the production of biologics as well as in medical technologies and industrial applications.

In January 2025, Danaher Corporation announced that it has signed a definitive agreement to sell its Pacific Scientific Aerospace business to Meggitt PLC, a global aerospace and defense company. Danaher simultaneously received a binding offer from Meggitt to acquire the Artus business which remains open for 12 months.

In October 2024, Eurofins Scientific has reached an agreement with SYNLAB to acquire its clinical diagnostics operations in Spain. The transaction is subject to customary conditions, including regulatory approvals, and is expected to close in 2025. SYNLAB's clinical diagnostics operations in Spain provide clinical diagnostics testing, including genetics and anatomical pathology services, throughout the country, achieving revenues of approximately €140m in 2023.

Types Covered:

  • Culture Methods
  • Urine Antigen Testing (UAT)
  • Polymerase Chain Reaction (PCR)
  • Serology
  • Direct Fluorescent Antibody (DFA) Test

Sample Types Covered:

  • Water
  • Biofilm
  • Swab Samples

Applications Covered:

  • Water Testing
  • In Vitro Diagnostics (IVD) Testing
  • Other Applications

End Users Covered:

  • Hospitals & Clinics
  • Diagnostic Laboratories
  • Water Treatment Industries
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Application Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Legionella Testing Market, By Type

  • 5.1 Introduction
  • 5.2 Culture Methods
  • 5.3 Urine Antigen Testing (UAT)
  • 5.4 Polymerase Chain Reaction (PCR)
  • 5.5 Serology
  • 5.6 Direct Fluorescent Antibody (DFA) Test

6 Global Legionella Testing Market, By Sample Type

  • 6.1 Introduction
  • 6.2 Water
  • 6.3 Biofilm
  • 6.4 Swab Samples

7 Global Legionella Testing Market, By Application

  • 7.1 Introduction
  • 7.2 Water Testing
    • 7.2.1 Microbial Culture
    • 7.2.2 DFA Stain
    • 7.2.3 PCR
  • 7.3 In Vitro Diagnostics (IVD) Testing
    • 7.3.1 Blood Culture and Sputum Tests
    • 7.3.2 Urinary Antigen Tests
    • 7.3.3 DFA Stain
    • 7.3.4 PCR
  • 7.4 Other Applications

8 Global Legionella Testing Market, By End User

  • 8.1 Introduction
  • 8.2 Hospitals & Clinics
  • 8.3 Diagnostic Laboratories
  • 8.4 Water Treatment Industries
  • 8.5 Other End Users

9 Global Legionella Testing Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 Danaher Corporation
  • 11.2 Quidel Corporation
  • 11.3 Thermo Fisher Scientific, Inc.
  • 11.4 Eurofins Scientific
  • 11.5 IDEXX Corporation
  • 11.6 Abbott Laboratories
  • 11.7 Merck KGaA
  • 11.8 Eiken Chemical Co., Ltd.
  • 11.9 Aquacert Ltd.
  • 11.10 Takara Bio, Inc.
  • 11.11 LuminUltra Technologies Ltd.
  • 11.12 Becton, Dickinson & Company
  • 11.13 Pro-Lab Diagnostics, Inc.
  • 11.14 Qiagen N.V.
  • 11.15 Bio-Rad Laboratories, Inc.

List of Tables

  • Table 1 Global Legionella Testing Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global Legionella Testing Market Outlook, By Type (2024-2032) ($MN)
  • Table 3 Global Legionella Testing Market Outlook, By Culture Methods (2024-2032) ($MN)
  • Table 4 Global Legionella Testing Market Outlook, By Urine Antigen Testing (UAT) (2024-2032) ($MN)
  • Table 5 Global Legionella Testing Market Outlook, By Polymerase Chain Reaction (PCR) (2024-2032) ($MN)
  • Table 6 Global Legionella Testing Market Outlook, By Serology (2024-2032) ($MN)
  • Table 7 Global Legionella Testing Market Outlook, By Direct Fluorescent Antibody (DFA) Test (2024-2032) ($MN)
  • Table 8 Global Legionella Testing Market Outlook, By Sample Type (2024-2032) ($MN)
  • Table 9 Global Legionella Testing Market Outlook, By Water (2024-2032) ($MN)
  • Table 10 Global Legionella Testing Market Outlook, By Biofilm (2024-2032) ($MN)
  • Table 11 Global Legionella Testing Market Outlook, By Swab Samples (2024-2032) ($MN)
  • Table 12 Global Legionella Testing Market Outlook, By Application (2024-2032) ($MN)
  • Table 13 Global Legionella Testing Market Outlook, By Water Testing (2024-2032) ($MN)
  • Table 14 Global Legionella Testing Market Outlook, By Microbial Culture (2024-2032) ($MN)
  • Table 15 Global Legionella Testing Market Outlook, By DFA Stain (2024-2032) ($MN)
  • Table 16 Global Legionella Testing Market Outlook, By PCR (2024-2032) ($MN)
  • Table 17 Global Legionella Testing Market Outlook, By In Vitro Diagnostics (IVD) Testing (2024-2032) ($MN)
  • Table 18 Global Legionella Testing Market Outlook, By Blood Culture and Sputum Tests (2024-2032) ($MN)
  • Table 19 Global Legionella Testing Market Outlook, By Urinary Antigen Tests (2024-2032) ($MN)
  • Table 20 Global Legionella Testing Market Outlook, By DFA Stain (2024-2032) ($MN)
  • Table 21 Global Legionella Testing Market Outlook, By PCR (2024-2032) ($MN)
  • Table 22 Global Legionella Testing Market Outlook, By Other Applications (2024-2032) ($MN)
  • Table 23 Global Legionella Testing Market Outlook, By End User (2024-2032) ($MN)
  • Table 24 Global Legionella Testing Market Outlook, By Hospitals & Clinics (2024-2032) ($MN)
  • Table 25 Global Legionella Testing Market Outlook, By Diagnostic Laboratories (2024-2032) ($MN)
  • Table 26 Global Legionella Testing Market Outlook, By Water Treatment Industries (2024-2032) ($MN)
  • Table 27 Global Legionella Testing Market Outlook, By Other End Users (2024-2032) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.